The Evolution of HTA in Emerging Markets Health-Care ... - TREE
The Evolution of HTA in Emerging Markets Health-Care ... - TREE
The Evolution of HTA in Emerging Markets Health-Care ... - TREE
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
OHE Consult<strong>in</strong>g Report for PhRMA<br />
5 January 2011<br />
1. Our accumulated knowledge and experience and that <strong>of</strong> our expert advisers as to the most<br />
relevant literature;<br />
2. Core references from past reviews <strong>of</strong> <strong>HTA</strong> processes to help <strong>in</strong> identify<strong>in</strong>g key authors <strong>in</strong> the<br />
fields.<br />
4.1.3 Workstream 3: Mapp<strong>in</strong>g <strong>HTA</strong> onto health care systems <strong>in</strong> emerg<strong>in</strong>g economies<br />
<strong>The</strong> third element <strong>of</strong> the project is to map the outputs <strong>of</strong> the Workstream 1 analysis <strong>of</strong> the evolution<br />
<strong>of</strong> health care systems onto the Workstream 2 analysis <strong>of</strong> options for <strong>HTA</strong>. This is <strong>in</strong>tended to<br />
enable us set out policy recommendations as to whether and <strong>in</strong> what way <strong>HTA</strong> processes can help<br />
lower <strong>in</strong>come and emerg<strong>in</strong>g economy countries to obta<strong>in</strong> more value for money from their health<br />
care expenditure whilst provid<strong>in</strong>g access to <strong>in</strong>novative technologies, <strong>in</strong>clud<strong>in</strong>g new medic<strong>in</strong>es, which<br />
can significantly improve health outcomes with<strong>in</strong> their systems. We do this <strong>in</strong> the context <strong>of</strong><br />
PhRMA’s perspective that it does not wish to promote the use <strong>of</strong> <strong>HTA</strong> where it doesn't exist but to<br />
be prepared with an appropriate response to engage and shape <strong>HTA</strong> when it is put forward.<br />
4.1.4 Workstream 4: Develop<strong>in</strong>g options for <strong>HTA</strong> development <strong>in</strong> the three countries<br />
We have complemented this approach with a more detailed analysis <strong>in</strong> the second part <strong>of</strong> the<br />
project on the use <strong>of</strong> and proposed use <strong>of</strong> <strong>HTA</strong> with<strong>in</strong> the three countries Brazil, Ch<strong>in</strong>a and Taiwan.<br />
<strong>The</strong>se three countries are selected as important markets <strong>in</strong> their own right, and because they span a<br />
range <strong>of</strong> different sorts <strong>of</strong> emerg<strong>in</strong>g markets with respect to size and state <strong>of</strong> development. For<br />
example, Brazil and Ch<strong>in</strong>a, along with India and Russia, comprise the large, powerful ‘BRIC’<br />
economies, although Brazil is considered <strong>in</strong> some classifications (e.g. FTSE) to have a higher state <strong>of</strong><br />
development than Ch<strong>in</strong>a. Taiwan is smaller than both, but <strong>in</strong> some classifications (e.g. Dow Jones) is<br />
considered to have achieved a level <strong>of</strong> development that puts it outside the emerg<strong>in</strong>g markets<br />
category.<br />
Ch<strong>in</strong>a Taiwan Brazil<br />
Dow Jones <br />
MSCI <br />
FTSE Advanced<br />
<br />
<br />
Emerg<strong>in</strong>g markets<br />
FTSE Secondary<br />
Emerg<strong>in</strong>g markets<br />
<br />
By l<strong>in</strong>k<strong>in</strong>g appropriate <strong>HTA</strong> use to the stage <strong>of</strong> health care system evolution we sought to translate<br />
the general analysis undertaken for the previous workstreams to <strong>in</strong>dicate potential <strong>HTA</strong> reform<br />
pathways relevant for these three countries when <strong>HTA</strong> is proposed by the government and/or<br />
payers. As part <strong>of</strong> this we have exam<strong>in</strong>ed how these markets are currently plann<strong>in</strong>g to use or us<strong>in</strong>g<br />
<strong>HTA</strong>. In particular we reviewed whether it is seen as a tool to improve effectiveness or as a cost-conta<strong>in</strong>ment<br />
tool. We aimed to identify reform options for PhRMA to consider and also to identify<br />
relevant op<strong>in</strong>ion leaders for these three countries. We took note <strong>of</strong> the PhRMA, IFPMA, and EFPIA<br />
21